Daily administration of paraprobiotic Lactobacillus gasseri CP2305 ameliorates chronic stress-associated symptoms in Japanese medical students

Administration of Lactobacillus gasseri CP2305 for 4 weeks improved stress-associated behaviours in healthy young adults and clinical symptoms in patients with irritable bowel syndrome. The present study was designed to confirm the stress-relieving effects of heat-inactivated, washed CP2305 (paraprobiotic CP2305) on 69 sixth-year medical students (40 males and 29 females) preparing to take the national examination for medical practitioners. Administration of the paraprobiotic CP2305 for 12 weeks significantly improved sleep quality assessed by both the Pittsburgh Sleep Quality Index and a one-channel sleep electroencephalogram during the pre-examination period compared with that of the placebo administration. The paraprobiotic CP2305 administration also prevented increases in basal salivary cortisol release and expression of stress-responsive microRNAs (miR-144 and miR-144⁄). In addition to the improvement in parasympathetic nerve activity, the paraprobiotic CP2305 normalized the bowel habits under the stressful conditions. Based on these results, we propose that paraprobiotic CP2305 may be used as a para-psychobiotic

Effect of fragmented Lactobacillus amylovorus CP1563 on lipid metabolism in overweight and mildly obese individuals: a randomized controlled trial

Background: Previously, we showed that fragmented Lactobacillus amylovorus CP1563 (CP1563) functions as a dual agonist of peroxisome proliferator-activated receptor α and γ in vitro and in vivo. Objective: Here, we examined the safety and effect of CP1563 ingestion on body fat in obese class I participants in a double-blinded, placebo-controlled, randomized clinical trial (RCT). Design: In the RCT, 200 participants with a body mass index (BMI) of 25–30 kg/m2 consumed test beverages with or without 200 mg of CP1563 daily for 12 weeks. In total, 197 subjects completed the study without any adverse effects. Results: Body fat percentage, whole body fat, and visceral fat were significantly decreased in the test group compared with the placebo group (p<0.001, p<0.001, and p<0.001, respectively). Triglycerides, total cholesterol, LDL-cholesterol, and diastolic blood pressure showed significant reductions in the test group compared with the placebo group (p<0.001, p<0.001, p<0.001, and p<0.001, respectively). Additionally, significant differences in the changes in blood glucose, insulin, homeostasis model assessment-insulin resistance (HOMA-IR), and uric acid were observed between the two groups (p<0.001, p=0.004, p<0.001, and p<0.001, respectively). Improvements in anthropometric measurements and markers were observed in obese class I subjects in the test group. Conclusions: Daily consumption of beverages containing fragmented CP1563 for 12 weeks by obese class I subjects improved anthropometric measurements and markers related to lipid and glucose metabolism without any adverse effects. These results suggest that the consumption of foods containing fragmented CP1563 reduces body fat and prevents metabolic syndrome